Protect Patients from Costly Care Act
Sponsored By: Representative Pappas
Introduced
Summary
Repeals recent changes to Medicaid cost-sharing and the orphan-drug exclusion in the Medicare drug price negotiation program. This bill would apply Title XIX and Title XI of the Social Security Act as if Sections 71120 and 71203 of Public Law 119-21 had never been enacted and would rescind the amounts appropriated under section 71120(c) of that law.
Show full summary
- Families and Medicaid enrollees: Would restore the prior Medicaid cost-sharing rules, which could change out-of-pocket charges for eligible households.
- Patients who use orphan drugs: Would restore the previous treatment of orphan drugs in Medicare's drug price negotiation program, reversing the amendment made by Section 71203.
- Federal finances: Would rescind the appropriation created by section 71120(c) of Public Law 119-21, removing that funding tied to the repealed Medicaid change.
Your PRIA Score
Personalized for You
How does this bill affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this bill and every other piece of legislation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Bill Overview
Analyzed Economic Effects
2 provisions identified: 1 benefits, 0 costs, 1 mixed.
Roll back Medicaid cost-sharing changes
The bill would undo recent Medicaid cost-sharing rules from Public Law 119-21. States would apply the prior Medicaid rules for copays and other charges. If you are on Medicaid, your out-of-pocket costs could be lower or stay the same versus those changes. The bill would also cancel the funding tied to those cost-sharing changes. These changes would take effect upon enactment.
Reverse Medicare drug negotiation rule change
The bill would undo a change to the Medicare Drug Price Negotiation Program involving orphan drugs. Agencies would apply the older rules instead. This mainly changes program policy and compliance. Any effect on drug prices for patients would be indirect and could vary. It would take effect upon enactment.
Sponsors & CoSponsors
Sponsor
Pappas
NH • D
Cosponsors
Jackson (IL)
IL • D
Sponsored 9/2/2025
Ruiz
CA • D
Sponsored 9/2/2025
Del. Norton, Eleanor Holmes [D-DC-At Large]
DC • D
Sponsored 9/2/2025
Fields
LA • D
Sponsored 9/2/2025
Larson (CT)
CT • D
Sponsored 9/2/2025
Carson
IN • D
Sponsored 9/2/2025
Thanedar
MI • D
Sponsored 9/2/2025
Craig
MN • D
Sponsored 9/2/2025
Goodlander
NH • D
Sponsored 9/2/2025
Roll Call Votes
No roll call votes available for this bill.
View on Congress.govTake It Personal
Get Your Personalized Policy View
Start a Free Government Policy Watch to see how policy affects your household, then upgrade to PRIA Full Coverage for year-round monitoring.
Already have an account? Sign in